Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight: a study within the Danish National Birth Cohort

Tina H Lassen, Mia Madsen, Lene T Skovgaard, Katrine Strandberg-Larsen, Jørn Olsen, Anne-Marie N Andersen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Smoking is a well-established risk factor for fetal growth restriction and other adverse pregnancy outcomes, and nicotine may be one of the chemical compounds that drive these associations. Nicotine replacement therapy (NRT) is a smoking cessation aid, which can facilitate smoking cessation. It is, however, unknown whether NRT used during pregnancy impairs fetal growth. The aim of this study was to estimate the association between the use of NRT during pregnancy and offspring birthweight. The study population consisted of 72 761 women enrolled in the Danish National Birth Cohort between 1996 and 2002. Information on NRT and potential confounders was obtained from two computer-assisted telephone interviews conducted in the second and third trimesters, respectively. Multiple linear regression in a multilevel model was used to estimate the association between NRT use and birthweight adjusted for gestational age and potential confounders. The adjusted analyses showed no significant association between the duration of NRT use and birthweight (b = 0.25 g per week of NRT use [95% CI -2.31, 2.81]) and neither was the type of NRT product (patch, gum, inhaler) associated with reduced birthweight. However, simultaneous use of more than one NRT product was associated with reduced birthweight (b = -10.73 g per week of NRT use [95% CI -26.51, 5.05]), although the association was not statistically significant. The results of this study suggest that maternal use of NRT in pregnancy does not seriously affect birthweight, but there could be a negative effect on birthweight associated with simultaneous use of more than one type of NRT product.
Original languageEnglish
JournalPaediatric and Perinatal Epidemiology
Volume24
Issue number3
Pages (from-to)272-81
Number of pages9
ISSN0269-5022
DOIs
Publication statusPublished - 1. May 2010

Fingerprint

Nicotine
Mothers
Smoking Cessation
Nebulizers and Vaporizers
Third Pregnancy Trimester
Gingiva
Second Pregnancy Trimester
Gestational Age
Linear Models
Smoking
Interviews

Cite this

Lassen, Tina H ; Madsen, Mia ; Skovgaard, Lene T ; Strandberg-Larsen, Katrine ; Olsen, Jørn ; Andersen, Anne-Marie N. / Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight : a study within the Danish National Birth Cohort. In: Paediatric and Perinatal Epidemiology. 2010 ; Vol. 24, No. 3. pp. 272-81.
@article{e677793064b211df9ac3000ea68e967b,
title = "Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight: a study within the Danish National Birth Cohort",
abstract = "Smoking is a well-established risk factor for fetal growth restriction and other adverse pregnancy outcomes, and nicotine may be one of the chemical compounds that drive these associations. Nicotine replacement therapy (NRT) is a smoking cessation aid, which can facilitate smoking cessation. It is, however, unknown whether NRT used during pregnancy impairs fetal growth. The aim of this study was to estimate the association between the use of NRT during pregnancy and offspring birthweight. The study population consisted of 72 761 women enrolled in the Danish National Birth Cohort between 1996 and 2002. Information on NRT and potential confounders was obtained from two computer-assisted telephone interviews conducted in the second and third trimesters, respectively. Multiple linear regression in a multilevel model was used to estimate the association between NRT use and birthweight adjusted for gestational age and potential confounders. The adjusted analyses showed no significant association between the duration of NRT use and birthweight (b = 0.25 g per week of NRT use [95{\%} CI -2.31, 2.81]) and neither was the type of NRT product (patch, gum, inhaler) associated with reduced birthweight. However, simultaneous use of more than one NRT product was associated with reduced birthweight (b = -10.73 g per week of NRT use [95{\%} CI -26.51, 5.05]), although the association was not statistically significant. The results of this study suggest that maternal use of NRT in pregnancy does not seriously affect birthweight, but there could be a negative effect on birthweight associated with simultaneous use of more than one type of NRT product.",
author = "Lassen, {Tina H} and Mia Madsen and Skovgaard, {Lene T} and Katrine Strandberg-Larsen and J{\o}rn Olsen and Andersen, {Anne-Marie N}",
year = "2010",
month = "5",
day = "1",
doi = "10.1111/j.1365-3016.2010.01104.x",
language = "English",
volume = "24",
pages = "272--81",
journal = "Paediatric and Perinatal Epidemiology (Print)",
issn = "0269-5022",
publisher = "Wiley-Blackwell",
number = "3",

}

Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight : a study within the Danish National Birth Cohort. / Lassen, Tina H; Madsen, Mia; Skovgaard, Lene T; Strandberg-Larsen, Katrine; Olsen, Jørn; Andersen, Anne-Marie N.

In: Paediatric and Perinatal Epidemiology, Vol. 24, No. 3, 01.05.2010, p. 272-81.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight

T2 - a study within the Danish National Birth Cohort

AU - Lassen, Tina H

AU - Madsen, Mia

AU - Skovgaard, Lene T

AU - Strandberg-Larsen, Katrine

AU - Olsen, Jørn

AU - Andersen, Anne-Marie N

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Smoking is a well-established risk factor for fetal growth restriction and other adverse pregnancy outcomes, and nicotine may be one of the chemical compounds that drive these associations. Nicotine replacement therapy (NRT) is a smoking cessation aid, which can facilitate smoking cessation. It is, however, unknown whether NRT used during pregnancy impairs fetal growth. The aim of this study was to estimate the association between the use of NRT during pregnancy and offspring birthweight. The study population consisted of 72 761 women enrolled in the Danish National Birth Cohort between 1996 and 2002. Information on NRT and potential confounders was obtained from two computer-assisted telephone interviews conducted in the second and third trimesters, respectively. Multiple linear regression in a multilevel model was used to estimate the association between NRT use and birthweight adjusted for gestational age and potential confounders. The adjusted analyses showed no significant association between the duration of NRT use and birthweight (b = 0.25 g per week of NRT use [95% CI -2.31, 2.81]) and neither was the type of NRT product (patch, gum, inhaler) associated with reduced birthweight. However, simultaneous use of more than one NRT product was associated with reduced birthweight (b = -10.73 g per week of NRT use [95% CI -26.51, 5.05]), although the association was not statistically significant. The results of this study suggest that maternal use of NRT in pregnancy does not seriously affect birthweight, but there could be a negative effect on birthweight associated with simultaneous use of more than one type of NRT product.

AB - Smoking is a well-established risk factor for fetal growth restriction and other adverse pregnancy outcomes, and nicotine may be one of the chemical compounds that drive these associations. Nicotine replacement therapy (NRT) is a smoking cessation aid, which can facilitate smoking cessation. It is, however, unknown whether NRT used during pregnancy impairs fetal growth. The aim of this study was to estimate the association between the use of NRT during pregnancy and offspring birthweight. The study population consisted of 72 761 women enrolled in the Danish National Birth Cohort between 1996 and 2002. Information on NRT and potential confounders was obtained from two computer-assisted telephone interviews conducted in the second and third trimesters, respectively. Multiple linear regression in a multilevel model was used to estimate the association between NRT use and birthweight adjusted for gestational age and potential confounders. The adjusted analyses showed no significant association between the duration of NRT use and birthweight (b = 0.25 g per week of NRT use [95% CI -2.31, 2.81]) and neither was the type of NRT product (patch, gum, inhaler) associated with reduced birthweight. However, simultaneous use of more than one NRT product was associated with reduced birthweight (b = -10.73 g per week of NRT use [95% CI -26.51, 5.05]), although the association was not statistically significant. The results of this study suggest that maternal use of NRT in pregnancy does not seriously affect birthweight, but there could be a negative effect on birthweight associated with simultaneous use of more than one type of NRT product.

U2 - 10.1111/j.1365-3016.2010.01104.x

DO - 10.1111/j.1365-3016.2010.01104.x

M3 - Journal article

C2 - 20415757

VL - 24

SP - 272

EP - 281

JO - Paediatric and Perinatal Epidemiology (Print)

JF - Paediatric and Perinatal Epidemiology (Print)

SN - 0269-5022

IS - 3

ER -